# A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

> **NCT00251459** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 5000 (—)

## Conditions studied

- Choroidal Neovascularization
- Age-related Macular Degeneration

## Interventions

- **DRUG:** rhuFab V2 (ranibizumab)

## Key facts

- **NCT ID:** NCT00251459
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 5000 (—)
- **Last updated:** 2014-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251459, "A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00251459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*